EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria

Lars Egevad iD, Brett Delahunt iD, Kenneth A Iczkowski, Theo van der Kwast, Geert J L H van Leenders iD, Katia R M Leite iD, Chin-Chen Pan iD, Hemamali Samaratunga, Toyonori Tsuzuki iD, Nita Mulliqi, Xiaoyi Ji, Henrik Olsson und 4 weitere

Histopathology · 2023

DOI: 10.1111/his.14867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Lars Egevad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Adenocarcinoma, Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: David and Astrid Hägelén Foundation, Orion Research Foundation, Oskar Huttunen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

There is strong evidence that cribriform morphology indicates a worse prognosis of prostatic adenocarcinoma. Our aim was to investigate its interobserver reproducibility in prostate needle biopsies. Methods and results A panel of nine prostate pathology experts from five continents independently reviewed 304 digitised biopsies for cribriform cancer according to recent International Society of Urological Pathology criteria. The biopsies were collected from a series of 702 biopsies that were reviewed by one of the panellists for enrichment of high‐grade cancer and potentially cribriform structures. A 2/3 consensus diagnosis of cribriform and noncribriform cancer was reached in 90% (272/304) of the biopsies with a mean kappa value of 0.56 (95% confidence interval 0.52–0.61). The prevalence of consensus cribriform cancers was estimated to 4%, 12%, 21%, and 20% of Gleason scores 7 (3 + 4), 7 (4 + 3), 8, and 9–10, respectively. More than two cribriform structures per level or a largest cribriform mass with ≥9 lumina or a diameter of ≥0.5 mm predicted a consensus diagnosis of cribriform cancer in 88% (70/80), 84% (87/103), and 90% (56/62), respectively, and noncribriform cancer in 3% (2/80), 5% (5/103), and 2% (1/62), respectively (all P < 0.01).

Conclusion

Cribriform prostate cancer was seen in a minority of needle biopsies with high‐grade cancer. Stringent diagnostic criteria enabled the identification of cribriform patterns and the generation of a large set of consensus cases for standardisation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaProstatic NeoplasmsMaleHumansProstateReproducibility of ResultsBiopsy, NeedleBiopsyNeoplasm Grading

Stichwörter der Autor:innen

cribriformgradingneedle biopsypathologyprostate cancerreproducibility

Autor:innen und Institutionen

  • Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Southern Community Laboratory, Wellington, New Zealand and Aquesta Uropathology, Brisbane, QLD, Australia.
  • Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Laboratory Medicine Program and Princess Margaret Cancer Center, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Urology, Laboratory of Medical Research, University of Sao Paulo Medical School, Sao Paulo, Brazil.

ORCID-Profile: Lars Egevad, Brett Delahunt, Geert J L H van Leenders, Katia R M Leite, Chin-Chen Pan, Toyonori Tsuzuki

Förderung

  • David and Astrid Hägelén Foundation
  • Orion Research Foundation
  • Oskar Huttunen Foundation
  • Wellcome Trust
  • Swedish Cancer Foundation
  • Orionin Tutkimussäätiö

Zitieren

APA

Egevad, L., Delahunt, B., Iczkowski, K. A., van der Kwast, T., van Leenders, G. J. L. H., Leite, K. R. M., Pan, C. C., Samaratunga, H., Tsuzuki, T., Mulliqi, N., Ji, X., Olsson, H., Valkonen, M., Ruusuvuori, P., Eklund, M., & Kartasalo, K. (2023). Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology. https://doi.org/10.1111/his.14867

Vancouver

Egevad L, Delahunt B, Iczkowski KA, van der Kwast T, van Leenders GJLH, Leite KRM, et al. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology. 2023. doi:10.1111/his.14867

BibTeX
@article{Egevad2023,
  author = {Egevad, Lars and Delahunt, Brett and Iczkowski, Kenneth A and van der Kwast, Theo and van Leenders, Geert J L H and Leite, Katia R M and Pan, Chin-Chen and Samaratunga, Hemamali and Tsuzuki, Toyonori and Mulliqi, Nita and Ji, Xiaoyi and Olsson, Henrik and Valkonen, Masi and Ruusuvuori, Pekka and Eklund, Martin and Kartasalo, Kimmo},
  title = {Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria},
  journal = {Histopathology},
  year = {2023},
  doi = {10.1111/his.14867}
}
Kostenlos starten →